UCLA Scientists Advance Gene Therapy for Deadly Blood Disorder

Strategic Insights -

Researchers at the University of California, Los Angeles (UCLA), have made significant progress in developing a stem cell gene therapy for alpha thalassemia major, a severe and inherited blood disorder that affects the production of hemoglobin. Led by Dr. Donald Kohn, a renowned gene therapy pioneer, the team has successfully restored normal alpha-globin protein production in patient cells in culture, enabling the modified cells to produce functional hemoglobin. This breakthrough has the potential to cure the disease, which currently requires lifelong specialized care and is often fatal.

Key Takeaways:

  • UCLA researchers have developed a stem cell gene therapy for alpha thalassemia major, a severe and inherited blood disorder, using a viral vector to deliver the alpha-globin gene to patient cells.
  • The therapy involves collecting a patient's own blood stem cells, adding the missing alpha-globin gene, and then returning the corrected cells to the patient.
  • In patient cells in culture, the gene therapy restored normal alpha-globin protein production to healthy levels, enabling the modified cells to produce functional hemoglobin.
  • The UCLA research team, led by Dr. Kohn, is working to complete preclinical studies and prepare a pre-investigational new drug package submission to the U.S. Food and Drug Administration (FDA) for clinical trials.
  • The therapy has the potential to cure alpha thalassemia major, a disease that is often fatal and requires lifelong specialized care.

Statistics:

  • 48 of 50 children with ADA-SCID (a type of severe combined immunodeficiency) were cured using Dr. Kohn's gene therapy (Source: UCLA Newsroom)
  • 4 copies of the genes required to produce hemoglobin are missing in individuals born with alpha thalassemia major, leading to severe health issues and early death (Source: UCLA).
  • 50% of children with alpha thalassemia major require lifelong blood transfusions, and 30% will die in infancy or early childhood due to complications (Source: UCLA).
  • The California Institute for Regenerative Medicine has awarded a grant to support preclinical studies and prepare a pre-investigational new drug package submission to the FDA for clinical trials (Source: UCLA).

Sources:

  • UCLA Newsroom
  • National Institutes of Health (NIH)
  • California Institute for Regenerative Medicine (CIRM)
  • Rose Hills Foundation
  • UCSF Center for Maternal-Fetal Precision Medicine